| Bioactivity | (+)-JNJ-A07 is a highly potent, orally active pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. (+)-JNJ-A07 exerts nanomolar to picomolar activity against a panel of 21 clinical isolates. (+)-JNJ-A07 has a favourable pharmacokinetic profile that results in outstanding efficacy against dengue virus infection in mouse infection models[1]. | |||||||||
| Invitro | (+)-JNJ-A07 has a high barrier to resistance and prevents the formation of the viral replication complex by blocking the interaction between two viral proteins (NS3 and NS4B)[1]. | |||||||||
| Name | (+)-JNJ-A07 | |||||||||
| CAS | 2135640-93-4 | |||||||||
| Formula | C28H26ClF3N2O6 | |||||||||
| Molar Mass | 578.96 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Kaptein SJF, et al. A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction [published correction appears in Nature. 2021 Nov;599(7883):E2]. Nature. 2021;598(7881):504-509. |
(+)-JNJ-A07
CAS: 2135640-93-4 F: C28H26ClF3N2O6 W: 578.96
(+)-JNJ-A07 is a highly potent, orally active pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. (+
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.